Payer Almanac
About the data Sign in
Star measuresDisplay measuresHEDISWhy members leave

Measures · D12 in 2019 · Part D · DD4 Drug Safety and Accuracy of Drug Pricing

Medication Adherence for Cholesterol (Statins)

Drug PlanMedication AdherenceSource: Prescription Drug Events

What it measures
Percent of plan members with a prescription for a cholesterol medication (a statin drug) who fill their prescription often enough to cover 80% or more of the time they are supposed to be taking the medication. One of the most important ways people with high cholesterol can manage their health is by taking medication as directed. The plan, the doctor, and the member can work together to do this.
How it's calculated
This measure is defined as the percent of Medicare Part D beneficiaries 18 years and older who adhere to their prescribed drug therapy for statin cholesterol medications. This percentage is calculated as the number of member-years of enrolled beneficiaries 18 years and older with a proportion of days covered (PDC) at 80 percent or higher for statin cholesterol medication(s) during the measurement period (numerator) divided by the number of member-years of enrolled beneficiaries 18 years and older with at least two statin cholesterol medication fills on unique dates of service during the measurement period (denominator). The PDC is the percent of days in the measurement period “covered” by prescription claims for the same medication or another in the therapeutic category. Beneficiaries are only included in the measure calculation if the first fill of their medication occurs at least 91 days before the end of the enrollment period. The Medication Adherence measure is adapted from the Medication Adherence- Proportion of Days Covered measure that was developed and endorsed by the Pharmacy Quality Alliance (PQA). See the medication list for this measure. The Medication Adherence rate is calculated using the National Drug Code (NDC) list and obsolete NDC date methodology maintained by the PQA. The complete NDC list is posted along with these technical notes. NDCs with obsolete dates are included in the measure calculation if the obsolete dates as reported by PQA are within the period of measurement (measurement year) or within six months prior to the beginning of the measurement year.
Data source
Prescription Drug Event (PDE) data The data for this measure come from PDE data files submitted by drug plans to Medicare by June 30, 2018 with dates of service from January 1, 2017-December 31, 2017. Only final action PDE claims are used to calculate this measure. PDE claims are limited to members who received at least two prescriptions on unique dates of service for statin drug(s). PDE adjustments made post-reconciliation are not reflected in this measure. Additional data sources include the Common Medicare Environment (CME), the Medicare Enrollment Database (EDB), and the Common Working File (CWF). • CME is used for enrollment information. • EDB is used for hospice enrollment. • CWF is used to identify inpatient stays for PDPs and MA-PDs, and skilled nursing facility stays for PDPs.
Measurement period
01/01/2017 – 12/31/2017
Better when
Higher
Weight
3 (Intermediate Outcome Measure)
Star assignment
Clustering
Case-mix adjusted
—
In improvement measure
Yes
Used in CAI
No
Exclusions
ShowContracts with 30 or fewer enrolled member-years (in the denominator)
Notes
Part D drugs do not include drugs or classes of drugs, or their medical uses, which may be excluded from coverage or otherwise restricted under section 1927(d)(2) of the Act, except for smoking cessation agents. As such, these drugs, which may be included in the medication or NDC lists, are excluded from CMS analyses. Also, the member-years of enrollment adjustment is made by CMS to account for partial enrollment within the benefit year. Enrollment is measured at the episode level, and inclusion in the measure is determined separately for each episode – i.e., to be included for a given episode, the beneficiary must meet the initial inclusion criteria for the measure during that episode. The measure is weighted based on the total number of member years for each episode in which the beneficiary meets the measure criteria. For instance, if a beneficiary is enrolled for a three-month episode, disenrolled for a six-month episode, reenrolled for a three-month episode, and meets the measure criteria during each enrollment episode, s/he will count as 0.5 member years in the rate calculation (3/12 + 3/12 = 6/12). The PDC calculation is adjusted for overlapping prescriptions for the same drug which is defined by active ingredient at the generic name level using the Medi-Span generic ingredient name. The calculation also adjusts for Part D beneficiaries’ stays in inpatient (IP) settings, hospice enrollments, and stays in skilled nursing facilities (SNFs). The SNF adjustment only applies to PDPs because SNF data are not currently available for MA-PDs. Please see Attachment L: Medication Adherence Measure Calculations for more information about these calculation adjustments. When available, beneficiary death date from the CME is the end date of a beneficiary’s measurement period. For contracts whose non-employer service area only covers Puerto Rico, the weight for this adherence measure is set to zero (0) when calculating the summary and overall rating. This weight of this measure remains three (3) within the improvement measure calculations for all contracts.
Disaster policy
Higher measure star (2018-2019) for contracts with 25% or more enrolled affected

From the 2019 Star Ratings Technical Notes (CMS).

Cut points over time

Score needed to earn each star level. Part D thresholds differ for MA-PD and standalone PDP contracts. Dotted lines and open dots: where the cut points may move for 2028.

How the 2028 cut points are projected

Each boundary moves by its median year-on-year change since 2019, capped at 5 points, the most CMS lets a non-survey cut point move in a year. It's the same projection the Star outlook uses for every contract. CMS sets real cut points from all contracts' scores each year, so treat these as a direction, not a forecast of the exact number.

StarsOrg type2027Projected 2028Move
2★MA-PD8487+3
3★MA-PD8889+1
4★MA-PD9091+1
5★MA-PD9394+1
2★PDP8687+1
3★PDP8889+1
4★PDP9091+1
5★PDP93930

2019 star distribution

Not rated: Plan too new to be measured (120); No data available (50); Plan not required to report measure (11); Not enough data available (9)

Cut point bands

Star yearOrg type1★2★3★4★5★
2027MA-PD< 84 %>= 84 % to < 88 %>= 88 % to < 90 %>= 90 % to < 93 %>= 93 %
2027PDP< 86 %>= 86 % to < 88 %>= 88 % to < 90 %>= 90 % to < 93 %>= 93 %
2026MA-PD< 84 %>= 84 % to < 88 %>= 88 % to < 90 %>= 90 % to < 93 %>= 93 %
2026PDP< 87 %>= 87 % to < 89 %>= 89 % to < 90 %>= 90 % to < 92 %>= 92 %
2025MA-PD< 80 %>= 80 % to < 85 %>= 85 % to < 89 %>= 89 % to < 93 %>= 93 %
2025PDP< 86 %>= 86 % to < 88 %>= 88 % to < 89 %>= 89 % to < 92 %>= 92 %
2024MA-PD< 82 %>= 82 % to < 86 %>= 86 % to < 88 %>= 88 % to < 91 %>= 91 %
2024PDP< 84 %>= 84 % to < 87 %>= 87 % to < 89 %>= 89 % to < 93 %>= 93 %
2023MA-PD< 81 %>= 81 % to < 85 %>= 85 % to < 88 %>= 88 % to < 92 %>= 92 %
2023PDP< 84 %>= 84 % to < 87 %>= 87 % to < 88 %>= 88 % to < 90 %>= 90 %
2022MA-PD< 78 %>= 78 % to < 83 %>= 83 % to < 87 %>= 87 % to < 91 %>= 91 %
2022PDP< 82 %>= 82 % to < 86 %>= 86 % to < 88 %>= 88 % to < 90 %>= 90 %
2021MA-PD< 75 %>= 75 % to < 83 %>= 83 % to < 86 %>= 86 % to < 88 %>= 88 %
2021PDP< 78 %>= 78 % to < 81 %>= 81 % to < 86 %>= 86 % to < 88 %>= 88 %
2020MA-PD< 72%? 72% to < 80%? 80% to < 84%? 84% to < 87%? 87%
2020PDP< 79%? 79% to < 83%? 83% to < 86%? 86% to < 88%? 88%
2019MA-PD< 73%? 73% to < 77%? 77% to < 83%? 83% to < 87%? 87%
2019PDP< 80%? 80% to < 82%? 82% to < 84%? 84% to < 88%? 88%
2018MA-PD< 66%? 66% to < 76%? 76% to < 80%? 80% to < 85%? 85%
2018PDP< 73%? 73% to < 79%? 79% to < 82%? 82% to < 86%? 86%
2017MA-PD< 66%? 66% to < 73%? 73% to < 77%? 77% to < 82%? 82%
2017PDP< 70%? 70% to < 74%? 74% to < 80%? 80% to < 84%? 84%
2016MA-PD< 50%? 50% to < 61%? 61% to < 73%? 73% to < 79%? 79%
2016PDP< 68%? 68% to < 73%? 73% to < 78%? 78% to < 83%? 83%
2015MA-PD< 59%? 59% to < 68%? 68% to < 76%? 76% to < 83%? 83%
2015PDP< 62%? 62% to < 69%? 69% to < 75%? 75% to < 78%? 78%

Lowest-scoring contracts, 2019

ContractParentMembersScoreStarsΔShortfall to 4★Pctile
S2874 HumanaHumana Inc.—5910250%
H8266 Constellation Health, Llc.Constellation Health, LLC.—5010330%
H7522 Medicare y Mucho Mas (MMM)Elevance Health, Inc.05410290%
H4876 Constellation Health, Llc.Constellation Health, LLC.—5610270%
H5577 MCS ClassicareMHH Healthcare, L.P.361,0205810251%
H2029 HumanaHumana Inc.05810251%
H4005 Triple-S AdvantageGuidewell Mutual Holding Corporation6,4905910241%
H9153 West Virginia Senior AdvantageSNP Holdings, LLC1,661611—221%
H3054 Constellation Health, Llc.Constellation Health, LLC.—6110221%
H5774 Triple S AdvantageGuidewell Mutual Holding Corporation121,3846210212%
S5983 Express Scripts MedicareCIGNA—781−162%
H6988 Anthem Blue Cross and Blue Shield HPElevance Health, Inc.10,1646410192%
H6672 Clear Spring HealthGroup 1001—671—162%
H5810 Molina Healthcare of CaliforniaMolina Healthcare, Inc.1,5006820153%
H5587 Blue Cross Blue Shield of Arizona Health ChoiceBlue Cross Blue Shield of Arizona8,603681−1153%
H4007 HumanaHumana Inc.—6820153%
H0062 WellcareCentene Corporation8,890681—153%
H8133 Blue Cross and Blue Shield of TexasHealth Care Service Corporation2,5076920144%
H7173 Wellcare by AllwellCentene Corporation—691−1144%
H9403 Clear Spring HealthGroup 1001—691—144%
S5617 HealthSpringHealth Care Service Corporation1,616,399791−154%
S7694 Elixir InsuranceRite Aid Corporation—791−154%
S5810 WellCareCentene Corporation—791−154%
S4607 Merit Health Insurance CompanyMagellan Health, Inc.—791−154%
H9276 AllwellCentene Corporation—701—134%

History

Star yearCodeNameMeasuredWeightSource
2027D10Medication Adherence for Cholesterol (Statins)01/01/2025 – 12/31/20253Prescription Drug Events
2026D10Medication Adherence for Cholesterol (Statins)01/01/2024 – 12/31/20243Prescription Drug Events
2025D10Medication Adherence for Cholesterol (Statins)01/01/2023 – 12/31/20233Prescription Drug Events
2024D10Medication Adherence for Cholesterol (Statins)01/01/2022 – 12/31/20223Prescription Drug Events
2023D10Medication Adherence for Cholesterol (Statins)01/01/2021 – 12/31/20213Prescription Drug Events
2022D10Medication Adherence for Cholesterol (Statins)01/01/2020 – 12/31/20203Prescription Drug Events
2021D12Medication Adherence for Cholesterol (Statins)01/01/2019 – 12/31/20193Prescription Drug Events
2020D12Medication Adherence for Cholesterol (Statins)01/01/2018 – 12/31/20183Prescription Drug Events
2019D12Medication Adherence for Cholesterol (Statins)01/01/2017 – 12/31/20173Prescription Drug Events
2018D13Medication Adherence for Cholesterol (Statins)01/01/2016 – 12/31/20163Prescription Drug Events
2017D14Medication Adherence for Cholesterol (Statins)01/01/2015 - 12/31/20153Prescription Drug Events
2016D14Medication Adherence for Cholesterol (Statins)01/01/2014 - 12/31/20143Prescription Drug Events
2015D13Medication Adherence for Cholesterol (Statins)01/01/2013 - 12/31/20133Prescription Drug Events